Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to enrollmentXx_NEWLINE_xXNo major surgery within 28 days prior to registrationXx_NEWLINE_xXAny major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 28 days prior to enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to enrollmentXx_NEWLINE_xXAny major surgery, extensive radiotherapy (> 15 days of treatment), chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to first dose of study treatment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to first dose of study treatmentXx_NEWLINE_xXNo history of major surgery =< 14 days prior to registrationXx_NEWLINE_xXNo history of major surgery =< 28 days of registrationXx_NEWLINE_xXNo major surgery =< 14 days prior to registrationXx_NEWLINE_xXPatients must not have received any major surgery or immunotherapy within 28 days prior to registrationXx_NEWLINE_xXIbrutinib must be discontinued 7 days before (when possible) until 7 days after major surgery, and 3 days before (when possible) until 3 days after minor surgery; thus, patients to be enrolled on an ibrutinib trial must have completed major surgery > 7 days before initiating treatment, and/or must have completed minor surgery > 3 days before initiating treatmentXx_NEWLINE_xXPatients must not have had major surgery within 28 days prior to registration or be scheduled for surgery during the projected course of protocol treatment; tumor biopsy is allowedXx_NEWLINE_xXNo major surgery within 21 days of registration with stabilization or resolution of surgical adverse eventsXx_NEWLINE_xXNo major surgery =< 7 days prior to registration and no minor surgery =< 3 days prior to registration (with the exception of intravenous access placement, e.g. Hickman or peripherally inserted central catheter [PICC])Xx_NEWLINE_xXMajor surgery within 21 days of starting protocol treatmentXx_NEWLINE_xXMajor surgery within 21 days of starting protocol treatmentXx_NEWLINE_xXMajor surgery within 30 days prior or during the study periodXx_NEWLINE_xXNo major surgery within 28 days prior to randomizationXx_NEWLINE_xXAny major surgery, extensive radiotherapy, chemotherapy with delayed toxicity (e.g. doxorubicin), biologic therapy, or immunotherapy within 21 days prior to enrollment and/or daily or weekly chemotherapy (e.g. sunitinib, sorafenib and pazopanib) without the potential for delayed toxicity within 14 days prior to enrollmentXx_NEWLINE_xX